Research Article

Optimal Catheter Ablation Strategy for Patients with Persistent Atrial Fibrillation and Heart Failure: A Retrospective Study

Table 1

Baseline clinical characteristics of the patients.

Total (n = 118)PVI only (n = 56)PVI + additional ablation (n = 62)

Age (years)63.7 ± 10.163.2 ± 9.964.1 ± 10.30.641
Male79 (66.9%)42 (75%)37 (59.7%)0.077
CAD48 (40.7%)25 (44.6%)23 (37.1%)0.405
Hypertension49 (41.5%)28 (50%)21 (33.9%)0.076
Diabetes mellitus25 (21.2%)13 (23.2%)12 (19.4%)0.608
Stroke/TIAs12 (10.2%)5 (8.9%)7 (11.3%)0.672
NYHA classification0.493
 I3 (2.5%)1 (1.8%)2 (3.2%)
 II41 (34.7%)22 (39.3%)19 (30.6%)
 III65 (55.1%)29 (51.8%)36 (58.1%)
 IV9 (7.6%)4 (7.1%)5 (8.1%)
CHA2DS2-VASc score2.4 ± 1.52.3 ± 1.42.5 ± 1.60.429
LAD (mm)44.0 ± 4.943.7 ± 5.444.3 ± 4.50.519
LVD (mm)53.2 ± 6.253.8 ± 6.352.8 ± 6.10.426
LVEF (%)38.4 ± 8.737.1 ± 8.239.6 ± 90.117
AF duration (years)2.7 ± 1.82.6 ± 1.62.9 ± 1.90.370
Average HR (BPM)89.4 ± 17.1188.8 ± 14.989.9 ± 18.80.768
BNP (pg/mL)465.3 [214.2, 745.6]431.4 [245.4, 821.7]376.9 [153.9, 738.8]0.455
Creatinine (μ mol/L)82.3 ± 20.684.3 ± 20.780.1 ± 20.40.318
ALT38.3 ± 27.938.8 ± 25.237.6 ± 31.00.836
AST30.6 ± 19.229.7 ± 15.731.5 ± 22.60.670
Hemoglobin (g/L)148.3 ± 17.4150.4 ± 16.1146.1 ± 18.60.224
HDL (mmol/L)2.2 ± 7.92.1 ± 7.52.4 ± 8.40.862
LDL (mmol/L)4.9 ± 17.34.5 ± 16.15.3 ± 18.60.838
TC (mmol/L)9.1 ± 32.58.6 ± 31.09.6 ± 33.10.892
Procedure time (min)130.6 ± 12.0123.1 ± 11.5137.4 ± 7.50.001
Ablation time (min)94.9 ± 12.884.2 ± 7.9104.5 ± 7.80.001

BPM: beats per minute; CAD: coronary artery disease; TIA: transient ischemic attacks; LAD: left atrial diameter; LVD: left ventricular diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; BNP: brain natriuretic peptide; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol.